27
Jan
2027

PCI Pharma Services

Exhibitor at Pharmapack Europe 2027 stand 4G92, General Zone
About Us

PCI Pharma Services is an integrated full service provider, a proven and trusted partner to leading companies in the global health care industry. We offer unparalleled expertise and experience in taking compounds from the earliest stages of development through to successful commercialization, delivering speed-to-market and commercial success for our customers.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    United States
  • On CPHI since:
    2015
  • Employees:
    1000 - 4999
Company types
CMO/CDMO
Contract Service
Primary activities
Other
View company profile
Contact info
Show contact info Hide contact info
Event information
Pharmapack Europe 2027
  • 27 Jan 2027 - 28 Jan 2027
  • Paris Expo, Porte de Versailles - Hall 4 | Paris, France
  • Visit us at stand 4G92, General Zone

Products Featured at Pharmapack Europe 2027

  • 1

    Product 1

    3
  • 5

    Product 5

    5
  • 6

    Product 6

    6
  • 7

    Product 7

    7
  • Biological derivatives

    Product Biological derivatives

    Pci pharma services offers clinical services which includes biological derivatives. Features: it is used in treatments of a number of diseases and injuries. Contact us for more information.

PCI Pharma Services Resources (1)

  • Bioavailability Enhancement Strategies for Targeted Protein Degraders

    Industry Webinar Bioavailability Enhancement Strategies for Targeted Protein Degraders

    Targeted protein degraders (TPDs), including PROTACs and molecular glues, represent a transformative therapeutic approach but face significant challenges in oral delivery due to their size, polarity, and poor solubility. Enhancing bioavailability is therefore critical to unlocking their full clinical potential. In this presentation, David O’Connell, Director of Scientific Affairs at PCI Pharma Services, will explore the latest bioavailability enhancement strategies for TPDs, from hot melt extrusion and nanomilling to advanced spray drying and nanotechnology. He will also highlight PCI’s strategic partnerships with leading solubility experts, enabling integrated, end-to-end solutions that accelerate development and improve outcomes for complex molecules.
    2025-11-06